SARS-CoV-2 Papain-Like Protease: Drug Design, Assay Development, and Drug Resistance.
This Account summarizes the group's effort to convert PLpro from a challenging target into a tractable antiviral drug-discovery platform and illustrates how integrated assay development, structural biology, medicinal chemistry, pharmacology, virology, and resistance analysis can transform a challenging viral deubiquitinase into a credible antiviral target.